Novartis Ag (NVS) Total Debt Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Total Debt Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.45% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 5.09% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.46% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -19.32% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 51.71% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.51% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -0.71% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -1.11% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.14% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 6.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.04% |
| Dec 31, 2025 | 8.61% |
| Jun 30, 2025 | 1.69% |
| Dec 31, 2024 | -9.90% |
| Jun 30, 2024 | -7.09% |
| Dec 31, 2023 | -11.94% |
| Jun 30, 2023 | -6.83% |
| Dec 31, 2022 | -1.49% |
| Jun 30, 2022 | 1.23% |
| Dec 31, 2021 | -3.16% |
| Jun 30, 2021 | 1.57% |
| Dec 31, 2020 | 8.10% |
| Jun 30, 2020 | 580.17% |
| Dec 31, 2019 | 4.78% |
| Jun 30, 2019 | 28.75% |
| Mar 31, 2019 | 26.02% |
| Dec 31, 2018 | 29.49% |
| Dec 31, 2017 | 1.04% |
| Dec 31, 2016 | 5.17% |
| Dec 31, 2015 | -12.23% |